2 http://fasb.org/srt/2026#ChiefExecutiveOfficerMember Q1 false 0001676047 --01-31 2027 NV 0001676047 2026-02-01 2026-04-30 0001676047 us-gaap:SubsequentEventMember 2026-06-01 0001676047 2026-02-13 2026-02-13 0001676047 2026-04-30 0001676047 ntrb:SorrentoTherapeuticsIncMember 2024-01-31 0001676047 2024-01-31 0001676047 2023-07-25 2023-07-25 0001676047 2022-02-01 2022-02-01 0001676047 2022-02-01 0001676047 ntrb:KindevaDrugDeliveryLPMember 2026-02-01 2026-04-30 0001676047 ntrb:MrGoodmanMember 2022-07-31 0001676047 srt:ChiefFinancialOfficerMember 2026-04-30 0001676047 2022-07-31 0001676047 us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 ntrb:FourPTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 ntrb:FourPTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 us-gaap:CorporateAndOtherMember us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 us-gaap:CorporateAndOtherMember us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 country:US us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 country:US us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 country:US us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 country:US us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:FourPTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:FourPTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:PoconoPharmaceuticalMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:PoconoPharmaceuticalMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:SellingGeneralAndAdministrativeCorporateMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrativeCorporateMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrative4PTherapeuticsMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 ntrb:SellingGeneralAndAdministrativePoconoPharmaceuticalsMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember 2026-04-30 0001676047 us-gaap:StockOptionMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourteenMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2026-02-01 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2026-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2026-02-01 2026-04-30 0001676047 us-gaap:EmployeeStockOptionMember 2026-04-30 0001676047 us-gaap:EmployeeStockOptionMember 2026-02-01 2026-04-30 0001676047 us-gaap:EmployeeStockOptionMember 2025-02-01 2026-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2026-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2025-01-31 2025-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2025-01-31 0001676047 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2025-02-01 2026-01-31 0001676047 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2025-02-01 2026-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2025-02-01 2026-01-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2026-01-31 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2026-01-31 0001676047 us-gaap:EmployeeStockOptionMember 2026-01-31 0001676047 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-03-20 0001676047 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-03-20 0001676047 us-gaap:EmployeeStockOptionMember 2021-11-03 0001676047 us-gaap:EmployeeStockOptionMember 2021-11-01 2021-11-01 0001676047 us-gaap:EmployeeStockOptionMember 2023-02-01 2023-02-01 0001676047 us-gaap:EmployeeStockOptionMember 2022-02-01 2022-02-01 0001676047 us-gaap:EmployeeStockOptionMember 2021-11-01 0001676047 us-gaap:WarrantMember 2026-04-30 0001676047 ntrb:ExercisePrices750Member us-gaap:WarrantMember 2026-04-30 0001676047 ntrb:ExercisePrices750Member us-gaap:WarrantMember 2026-02-01 2026-04-30 0001676047 ntrb:ExercisePrices643Member us-gaap:WarrantMember 2026-04-30 0001676047 ntrb:ExercisePrices643Member us-gaap:WarrantMember 2026-02-01 2026-04-30 0001676047 ntrb:ExercisePriceSixPointZeroZeroMember us-gaap:WarrantMember 2026-04-30 0001676047 ntrb:ExercisePriceSixPointZeroZeroMember us-gaap:WarrantMember 2026-02-01 2026-04-30 0001676047 ntrb:ExercisePriceFourPointZeroZeroMember us-gaap:WarrantMember 2026-04-30 0001676047 ntrb:ExercisePriceFourPointZeroZeroMember us-gaap:WarrantMember 2026-02-01 2026-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreePointSevenThreeMember 2026-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreePointSevenThreeMember 2026-02-01 2026-04-30 0001676047 us-gaap:WarrantMember 2026-02-01 2026-04-30 0001676047 us-gaap:WarrantMember 2025-02-01 2026-01-31 0001676047 us-gaap:WarrantMember 2026-01-31 0001676047 us-gaap:WarrantMember 2025-01-31 2025-01-31 0001676047 us-gaap:WarrantMember 2025-01-31 0001676047 us-gaap:WarrantMember 2026-03-31 0001676047 us-gaap:WarrantMember 2025-09-30 0001676047 us-gaap:CommonStockMember us-gaap:WarrantMember 2025-02-01 2025-02-28 0001676047 ntrb:ConsultantMember us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001676047 2025-02-01 2025-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2025-03-04 0001676047 2025-04-30 0001676047 srt:MaximumMember 2022-08-04 0001676047 srt:MinimumMember 2022-08-04 0001676047 srt:DirectorMember 2022-07-26 2022-07-26 0001676047 us-gaap:PreferredStockMember 2025-07-09 2025-07-09 0001676047 us-gaap:SeriesAPreferredStockMember 2025-07-09 2025-07-09 0001676047 us-gaap:CommonStockMember 2025-07-09 0001676047 us-gaap:SeriesAPreferredStockMember 2025-07-09 0001676047 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2025-07-09 0001676047 us-gaap:PreferredStockMember 2016-01-15 0001676047 srt:ChiefExecutiveOfficerMember 2026-04-30 0001676047 2026-01-31 0001676047 us-gaap:IntellectualPropertyMember 2026-01-31 0001676047 us-gaap:IntellectualPropertyMember 2026-04-30 0001676047 ntrb:CustomerBaseMember 2026-01-31 0001676047 ntrb:CustomerBaseMember 2026-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2025-02-01 2025-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2026-02-01 2026-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2023-07-19 0001676047 ntrb:NotePayableRelatedPartyMember 2025-02-01 2025-04-30 0001676047 ntrb:NotePayableRelatedPartyMember 2026-02-01 2026-04-30 0001676047 ntrb:NotePayableRelatedPartyMember 2026-01-31 0001676047 ntrb:NotePayableRelatedPartyMember 2026-04-30 0001676047 ntrb:NotePayableRelatedPartyMember 2024-05-15 0001676047 ntrb:NotePayableRelatedPartyMember 2024-02-01 2024-10-31 0001676047 ntrb:NotePayableRelatedPartyMember 2023-07-17 0001676047 us-gaap:LineOfCreditMember ntrb:NotePayableRelatedPartyMember 2023-07-17 0001676047 ntrb:AutomobileMember 2026-01-31 0001676047 ntrb:AutomobileMember 2026-04-30 0001676047 ntrb:AutomobileMember 2022-04-03 2022-04-03 0001676047 ntrb:AutomobileMember 2022-04-03 0001676047 us-gaap:LineOfCreditMember 2026-01-31 0001676047 us-gaap:LineOfCreditMember 2026-04-30 0001676047 us-gaap:LineOfCreditMember 2026-02-01 2026-04-30 0001676047 ntrb:CostOfGoodsSoldMember 2025-02-01 2025-04-30 0001676047 ntrb:CostOfGoodsSoldMember 2026-02-01 2026-04-30 0001676047 us-gaap:FurnitureAndFixturesMember 2026-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2026-04-30 0001676047 us-gaap:MachineryAndEquipmentMember 2026-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2026-04-30 0001676047 us-gaap:EquipmentMember 2026-01-31 0001676047 us-gaap:EquipmentMember 2026-04-30 0001676047 ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember 2020-08-31 0001676047 ntrb:FourPTherapeuticsLLCMember 2026-04-30 0001676047 country:US 2025-02-01 2025-04-30 0001676047 country:US 2026-02-01 2026-04-30 0001676047 ntrb:SaleOfGoodsMember 2025-02-01 2025-04-30 0001676047 ntrb:SaleOfGoodsMember 2026-02-01 2026-04-30 0001676047 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ntrb:CustomerDMember 2026-02-01 2026-04-30 0001676047 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ntrb:CustomerCMember 2026-02-01 2026-04-30 0001676047 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ntrb:CustomerBMember 2026-02-01 2026-04-30 0001676047 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ntrb:CustomerAMember 2026-02-01 2026-04-30 0001676047 ntrb:CreditLineNoteFacilityMember 2024-04-19 2024-04-19 0001676047 us-gaap:RelatedPartyMember ntrb:CreditLineNoteFacilityMember 2023-07-17 0001676047 us-gaap:RelatedPartyMember ntrb:CreditLineNoteFacilityMember 2023-03-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2020-08-31 0001676047 2018-08-01 0001676047 ntrb:FourPTherapeuticsLLCMember 2018-08-01 0001676047 us-gaap:CommonStockMember ntrb:FourPTherapeuticsLLCMember 2018-08-01 0001676047 us-gaap:CommonStockMember ntrb:FourPTherapeuticsLLCMember 2018-08-01 2018-08-01 0001676047 2025-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2025-04-30 0001676047 us-gaap:RetainedEarningsMember 2025-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001676047 us-gaap:CommonStockMember 2025-04-30 0001676047 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0001676047 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2025-02-01 2025-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2025-01-31 0001676047 us-gaap:RetainedEarningsMember 2025-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001676047 us-gaap:CommonStockMember 2025-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2026-04-30 0001676047 us-gaap:RetainedEarningsMember 2026-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001676047 us-gaap:PreferredStockMember 2026-04-30 0001676047 us-gaap:CommonStockMember 2026-04-30 0001676047 us-gaap:RetainedEarningsMember 2026-02-01 2026-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2026-02-01 2026-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2026-01-31 0001676047 us-gaap:RetainedEarningsMember 2026-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0001676047 us-gaap:PreferredStockMember 2026-01-31 0001676047 us-gaap:CommonStockMember 2026-01-31 0001676047 2026-06-11 0001676047 ntrb:Warrants1Member 2026-02-01 2026-04-30 0001676047 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001676047 us-gaap:PreferredStockMember 2025-01-31 0001676047 us-gaap:PreferredStockMember 2025-02-01 2025-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-02-01 2025-04-30 0001676047 ntrb:GoodwillAndIntangiblesImpairmentMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 ntrb:GoodwillAndIntangiblesImpairmentMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 us-gaap:CorporateAndOtherMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 us-gaap:CorporateAndOtherMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 us-gaap:NonUsMember us-gaap:ReportableSubsegmentsMember 2026-02-01 2026-04-30 0001676047 us-gaap:NonUsMember us-gaap:ReportableSubsegmentsMember 2025-02-01 2025-04-30 0001676047 us-gaap:NonUsMember us-gaap:ReportableSubsegmentsMember 2026-04-30 0001676047 us-gaap:NonUsMember us-gaap:ReportableSubsegmentsMember 2026-01-31 0001676047 us-gaap:ServiceMember 2026-02-01 2026-04-30 0001676047 us-gaap:ServiceMember 2025-02-01 2025-04-30 0001676047 us-gaap:NonUsMember 2026-02-01 2026-04-30 0001676047 us-gaap:NonUsMember 2025-02-01 2025-04-30 0001676047 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001676047 us-gaap:PreferredStockMember 2026-02-01 2026-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-02-01 2026-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2026-02-01 2026-04-30 0001676047 us-gaap:RelatedPartyMember 2025-02-01 2025-04-30 0001676047 us-gaap:PreferredStockMember 2025-04-30 iso4217:USD utr:sqft xbrli:pure iso4217:USD xbrli:shares xbrli:shares ntrb:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 000-40854

NUTRIBAND INC.

(Exact name of registrant as specified in its charter)

NEVADA		81-1118176
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

121 South Orange Ave., Suite 1500, Orlando, FL		32801
(Address of Principal Executive Offices)		(Zip Code)

(407) 377-6695

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	NTRB	The Nasdaq Stock Market LLC
Warrants	NTRBW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the issuer’s common stock, par value $0.001 per share, was 12,155,983 shares as of June 11, 2026

NUTRIBAND INC.

INDEX

		Page No.
Part I: Financial Information		1

Item 1	Financial Statements	1
	Consolidated Balance Sheets as of April 30, 2026 (unaudited) and January 31, 2026.	2
	Consolidated Statements of Operations for the three months ended April 30, 2026 and 2025 (unaudited),	3
	Consolidated Statements of Stockholders’ Equity for the three months ended April 30, 2026, and 2025 (unaudited)	4
	Consolidated Statements of Cash Flows for the three months ended April 30, 2026, and 2025 (unaudited)	5
	Notes to Unaudited Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3	Quantitative and Qualitative Disclosures about Market Risk	21
Item 4	Controls and Procedures	21

Part II: Other Information		22

Item 1.	Legal Proceedings	22
Item 1A	Risk Factors	22
Item 6	Exhibits	24

NUTRIBAND INC.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America have been condensed or omitted from the following financial statements pursuant to the rules and regulations of the Securities and Exchange Commission.

The results of operations for the three months ended April 30, 2026 and 2025, are not necessarily indicative of the results for the entire fiscal year or for any other period.

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	April 30,			January 31,
	2026			2026
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	4,006,184		$	4,574,857
Accounts receivable-net		2,632			118,404
Inventory-net		121,494			117,987
Prepaid expenses		245,952			177,470
Total Current Assets		4,376,262			4,988,718

PROPERTY & EQUIPMENT-net		548,244			567,255

OTHER ASSETS:
Goodwill		1,719,535			1,719,535
Operating lease right of use asset		63,000			72,000
Intangible assets-net		185,261			200,427

TOTAL ASSETS	$	6,892,302		$	7,547,935

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	639,192		$	502,654
Deferred revenue		30,406			120,303
Operating lease liability-current portion		33,201			32,453
Notes payable-current portion		129,338			128,871
Total Current Liabilities		832,137			784,281

LONG-TERM LIABILITIES:
Note payable-net of current portion		29,825			35,861
Operating lease liability-net of current portion		40,350			48,305
Total Liabilities		902,312			868,447

Commitments and Contingencies		-			-

STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, 3,008,643 and 3,008,643 issued and outstanding as of April 30, 2026 and January 31,2026, respectively		3,009			3,009
Common stock, $.001 par value, 291,666,666 shares authorized, 12,174,883 and 12,174,883 shares issued as of April 30,2026 and January 31,2026, respectively, 12,155,983 and 12,155,983 shares outstanding as of April 30, 2026 and January 31, 2026, respectively		12,156			12,156
Additional paid-in-capital		53,996,205			53,443,747
Accumulated other comprehensive loss		(304	)		(304	)
Treasury stock, 18,900 and 18,900 shares at cost, as of April 30, 2026 and January 31, 2026, respectively		(86,852	)		(86,852	)
Accumulated deficit		(47,934,224	)		(46,692,268	)
Total Stockholders’ Equity		5,989,990			6,679,488

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	6,892,302		$	7,547,935

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	For the Three Months Ended
	April 30,
	2026			2025

Revenue	$	433,399		$	667,432

Costs and expenses:
Cost of revenues		236,598			415,451
Research and development		247,261			683,426
Selling, general and administrative		1,203,891			982,052
Total Costs and Expenses		1,687,750			2,080,929

Loss from operations		(1,254,351	)		(1,413,497	)

Other income (expense):
Other income		17,403			30,508
Interest expense		(5,008	)		(5,880	)
Total other income (expense)		12,395			24,628

Loss before provision for income taxes		(1,241,956	)		(1,388,869	)

Provision for income taxes		-			-

Net loss	$	(1,241,956	)	$	(1,388,869	)

Preferred shares dividend		-			-

Net loss available to common stockholders - basic and diluted	$	(1,241,956	)	$	(1,388,869	)

Net loss per share attributable to common stockholders - basic and diluted	$	(0.10	)	$	(0.12	)

Weighted average common shares outstanding - basic and diluted		12,155,983			11,125,800

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)

Three Months Ended April 30, 2026

														Accumulated
				Common Stock				Preferred Stock				Additional		Other
				Number of				Number of				Paid In		Comprehensive			Accumulated			Treasury
	Total			shares		Amount		shares		Amount		Capital		Income(Loss)			Deficit			Stock
Balance, February 1, 2026		6,679,488			12,155,983	$	12,156		3,008,643	$	3,009	$	53,443,747	$	(304	)	$	(46,692,268	)	$	(86,852	)

Warrants issued for services		552,458			-		-		-		-		552,458		-			-			-

Net loss		(1,241,956	)		-		-		-		-		-		-			(1,241,956	)		-

Balance, April 30, 2026	$	5,989,990			12,155,983	$	12,156		3,008,643	$	3,009	$	53,996,205	$	(304	)	$	(47,934,224	)	$	(86,852	)

Three Months Ended April 30, 2025

															Accumulated
				Common Stock				Preferred Stock				Additional			Other
				Number of				Number of				Paid In			Comprehensive			Accumulated			Treasury
	Total			shares		Amount		shares		Amount		Capital			Income(Loss)			Deficit			Stock
Balance, February 1, 2025	$	6,428,905			11,074,810	$	11,075		-	$	-	$	45,029,317		$	(304	)	$	(38,462,636	)	$	(148,547	)

Treasury stock issued for services		63,350			8,500		9		-		-		24,496			-			-			38,845

Cashless exercise of warrants		-			46,961		46		-		-		(46	)		-			-			-

Net loss		(1,388,869	)		-		-		-		-		-			-			(1,388,869	)		-

Balance, April 30, 2025	$	5,103,386			11,130,271	$	11,130		-	$	-	$	45,053,767		$	(304	)	$	(39,851,505	)	$	(109,702	)

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	For the Three Months Ended
	April 30,
	2026			2025
Cash flows from operating activities:
Net loss	$	(1,241,956	)	$	(1,388,869	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		34,177			57,480
Operating lease expense		9,000			9,000
Loss on extinguishment of debt		-			-
Goodwill and intangible impairment					-
Stock-based compensation-shares issued for services		-			63,350
Stock-based compensation-options and warrants		552,458			-
Changes in operating assets and liabilities:
Accounts receivable		115,772			(20,289	)
Prepaid expenses		(68,483	)		40,568
Inventories		(3,507	)		(3,283	)
Deferred revenue		(89,897	)		(111,200	)
Operating lease liability		(7,207	)		(6,579	)
Accounts payable and accrued expenses		136,539			22,850
Net Cash Used In Operating Activities		(563,104	)		(1,336,972	)

Cash flows from investing activities:
Purchase of equipment		-			(5,324	)
Net Cash Used in Investing Activities		-			(5,324	)

Cash flows from financing activities:
Proceeds from note payable-related party		-			-
Proceeds from the exercise of employee stock options		-
Proceeds from sale of common stock and exercise of warrants		-			-
Purchase of treasury stock					-
Payment on note payable		(5,569	)		(5,324	)
Net Cash Provided by Financing Activities		(5,569	)		(5,324	)

Net change in cash		(568,673	)		(1,347,620	)

Cash and cash equivalents - Beginning of period		4,574,857			4,311,719

Cash and cash equivalents - End of period	$	4,006,184		$	2,964,099

Supplementary information:

Cash paid for:
Interest	$	1,250		$	621

Income taxes	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities:

Cashless conversion of warrants	$	-		$	46

Measurement of operating lease right-of-use assets and liabilities	$	-		$	108,000

See notes to unaudited consolidated financial statements

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Three Months Ended April 30, 2026 and 2025

ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics was a director of the Company from April 2018, when the Company entered into an agreement to acquire 4P Therapeutics until he resigned as a director in January 2022.

4P Therapeutics is engaged in the development of transdermal pharmaceutical products. With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The primary focus of the business is to incorporate the Company’s Aversa abuse deterrent technology into transdermal patches containing already approved drugs. Although these drugs are already approved, the Company needs to conduct a product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical businesses of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

Pocono Pharmaceuticals is a coated products contract development and manufacturing organization that supports their customers with product design, development and manufacturing services. Pocono Pharmaceuticals has specialized expertise and state-of-the-art manufacturing capabilities for topical, transdermal and kinesiology tape products. Active Intelligence manufactures activated kinesiology tape for customers in the sports and physical markets.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited Financial Statements

The consolidated balance sheet as of April 30, 2026, and the consolidated statements of operations, stockholders’ equity and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) to prepare fairly the financial position, results of operations and cash flows for all periods presented have been made. The results for the three months ending April 30, 2026, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with consolidated financial statements and footnotes therein included in Nutriband’s Annual Report on Form 10-K for the year ending January 31, 2026.

Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (SEC”). The preparation of consolidated statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and accompanying footnotes. Actual results could differ from estimates.

The Company’s significant accounting policies are in Note 2 in the Company’s Annual Report on Form 10-K for the ending January 31, 2026. There were no significant changes to these accounting policies during the three months ending April 30, 2026.

Going Concern Assessment

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved, and management has the proper authority to execute them within the look-forward period.

As of April 30, 2026, the Company had cash and cash equivalents of $4,006,184 and working capital of $3,544,125. For the three months ended April 30, 2026, the Company incurred a net loss from operations of $1,254,351 and used cash flow from operations of $563,104. The Company has generated operating losses since its inception and has relied on sales of securities and the issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 17, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors. During the year ended January 31, 2026, the Company received proceeds of $5,425,709 from the exercise of warrants and employee stock options.

Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Revenue Types

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

Contract research and development services for pharmaceutical and medical device life sciences customers with revenues listed under services.

Contracts with Customers

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

The Company’s revenues include significant concentration from a limited number of customers. For the three months ended April 30, 2026, Customer A, Customer B, Customer C, and Customer D accounted for approximately 25%, 20%, 14%, and 10% of the Company’s total consolidated revenues.

Contract Liabilities

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of accounts in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

	Three Months Ending
	April 30,
	2026		2025
Revenue by type:
Sale of goods	$	433,399	$	667,432
Services		-		-
Total	$	433,399	$	667,432

	Three Months Ending
	April 30,
	2026		2025
Revenue by geographic location:
United States	$	433,399	$	667,432
Foreign		-		-
Total	$	433,399	$	667,432

Goodwill

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. As of April 30, 2026 and January 31, 2026, Goodwill amounted to $1,719,535 and $1,719,535, respectively.

Recent Accounting Standards

The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

PROPERTY AND EQUIPMENT

	April 30,			January 31,
	2026			2026
Lab equipment	$	144,585		$	144,585
Machinery and equipment		1,389,756			1,389,756
Furniture and Fixtures		19,643			19,643
Total		1,553,984			1,553,984

Less: Accumulated depreciation		(1,005,740	)		(986,729	)
Net Property and Equipment	$	548,244		$	567,255

Depreciation expenses amounted to $19,011 and $42,314 for the three months ended April 30, 2026, and 2025, respectively. During the three months ended April 30, 2026, and 2025, depreciation expenses of $15,208 and $33,851, respectively, have been allocated to the cost of goods sold.

NOTES PAYABLE

Notes Payable

Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the three months ended April 30, 2026, the Company made $4,380 of principal payments. As of April 30, 2026, the amount due was $47,798, of which $17,973 is current. As of January 31, 2026, the amount due was $52,178.

On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of April 30, 2026, the amount due was $4,837, all of which is current. As of January 31, 2026, the amount due was $6,026.

Note payable-related party.

On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility to the Company entered on March 17, 2023. Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. The Company received advances of $300,000 during the nine months ended October 31, 2024. On May 15, 2024, the Company agreed to convert the $300,000 debt. The conversion was made pursuant to the terms of a Conversion Agreement, which provided the conversion of $300,000 of principal and $4,922 of accrued interest. The Company issued 76,230 shares of common stock and 152,460 warrants exercisable at $6.43 per share, resulting in a $368,036 loss on extinguishment. As of April 30, 2026 and January 31, 2026 , the balance due was $-0- and $-0-, respectively. The Company recorded interest expense of $-0- and $-0- for the three months ended April 30, 2026, and 2025, respectively.

Secured borrowing liability.

On July 19, 2023, the Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the three months ended April 30, 2026, and 2025, the Company recorded an interest expense of $2,549 and $2,549, respectively.

Interest expenses for the three months ended April 30, 2026, and 2025, were $5,008 and $5,880, respectively.

INTANGIBLE ASSETS

As of April 30, 2026 and January 31, 2026, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

	April 30,			January 3,
	2026			2026
Customer base	$	214,640		$	214,640
Intellectual property and trademarks		623,822			623,822
Total		838,462			838,462

Less: Accumulated amortization		(653,201	)		(638,035	)
Net Intangible Assets	$	185,261		$	200,427

Amortization expenses for the three months ended April 30, 2026 and 2025 amounted to $15,166 and $113,150, respectively. There was no impairment charges during the three months ended April 30, 2026.

	Total
Year Ended January 31,
2027	$	45,500
2028		60,666
2029		41,736
2030		23,596
2031		13,763
	$	185,261

RELATED PARTY TRANSACTIONS

Activity during the three months ended April 30, 2026

During the three months ended April 30, 2026, a director of the Company and a related party were issued warrants to purchase 206,080 shares of common stock at an exercise price of $3.73 per share.

Activity during the three months ended April 30, 2025

There were no related party transactions during the three months ended April 30, 2025.

STOCKHOLDERS’ EQUITY

Preferred Stock

On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

On July 9,2025, the board of directors created a series of non-voting preferred stock consisting initially of shares designated as the Series A Convertible Preferred Stock (the “the Series A Preferred Stock”). The terms of the Series A Preferred Stock provide that, following the date of the approval for commercial sale by the Federal Drug Administration of the Company’s transdermal pharmaceutical products that are based on the Company’s AVERSA abuse deterrent technology, each share of Series A Preferred Stock will be convertible at the option of the holder into one share of Common Stock. The holders of Series A Preferred Stock that do not convert their shares shall be eligible for dividends as declared by the board of directors for those holders of the Series A Preferred Stock, and the Series A Preferred Stock is also eligible for dividends declared by the board of directors on the class of common stock.

The Company authorized on July 9, 2025, a preferred stock dividend to be issued by the Company to all shareholders on the basis of one share of Series A Preferred stock issued for each four shares of common stock owned by the holder. The record date for the dividend was July 25, 2025. On the date of distribution of the dividend, 3,008,643 shares of the Series A Preferred Stock were issued to our shareholders. The fair value of the preferred stock dividend was $21,814,166.

Common Stock

On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

Activity during the Three Months Ended April 30, 2026

(a)

There were no stock transactions during the three months ending April 30, 2026.

Activity during the Three Months Ended April 30, 2025

(a)

As of April 30, 2025, the Company held 23,900 shares of treasury stock. On March 4, 2025, 3,500 shares of treasury stock held by the Company were issued to employees for services rendered. The Company recorded an expense of $24,360 during the three months ending April 30, 2025, in connection with the transaction.

(b)

On February 8, 2025, the Company entered into an agreement with a consultant to provide consulting services to the Company’s Board of Directors. The Company issued 5,000 shares of the Company’s common stock to the consultant, valued at $39,050 and expensed during the three months ending April 30, 2025. The shares were issued from the treasury shares held by the Company. The term of the agreement is for twelve months.

(c)

In February 2025, the Company’s outside counsel exercised 58,433 warrants as a cashless conversion and the Company issued 46,961 shares of common stock.

OPTIONS and WARRANTS

Warrants

In September 2025, the Company issued 340,393 warrants to investors for services rendered, including a director and a related party of the Company. The warrants are exercisable at a price of $6.00 per share and expire three years from the date of issuance. The Company recorded a non-cash expense of $1,250,264 during the year ended January 31, 2026.

The Company used the Black Scholes valuation model to record fair value of the warrants issued during the year ending January 31, 2026. The valuation model used a dividend rate of 0%; expected terms of 2.5 years; volatility rates of 105%; and risk-free rate of 4%.

In March 2026, the Company issued 340,393 warrants to investors for services rendered, including a director and a related party of the Company. The warrants vested immediately and are exercisable at a price of $3.73 per share and expire three years from the date of issuance. The Company recorded a non-cash expense of $552,458 during the three months ended April 30, 2026.

The Company used the Black Scholes valuation model to record fair value of the warrants issued during the three months ending April 30, 2026. The valuation model used a dividend rate of 0%; expected terms of 1.5 years: volatility rates of 90%; and risk-free rate of 3,7%.

The following table summarizes the changes in the outstanding warrants and the related price of the shares of the common stock issued to non-employees of the Company during the years ended January 31, 2026 and 2025.

				Exercise		Remaining	Intrinsic
	Shares			Price		Life	Value
Outstanding, January 31, 2025		5,546,973		$	5.89	3.68 years	$	-

Granted		340,393			6.00	3.22 years		-

Expired/Cancelled		-			-	-		-

Exercised		(982,010	)		6.16	-		-

Outstanding, January 31, 2026		4,905,356			6.39	3.68 years		-

Granted		340,393			3.73	2.98 years		-

Expired/Cancelled		-			-	-		-

Exercised		-			-	-		-

Outstanding - April 30, 2026		5,245,749		$	6.22	2.98 years	$	47,655

Exercisable - April 30, 2026		5,245,749		$	6.22	2.98 years	$	47,655

The following table summarizes additional information relating to the warrants outstanding as of April 30, 2026:

Range of Exercise Prices		Number Outstanding		Remaining Contractual Life (Years)		Exercise Price for Shares Outstanding		Number Exercisable		Exercise Price for Shares Exercisable		Intrinsic Value

$	3.73		340,393		4.37	$	3.73		340,393	$	3.73	$	47,655
$	4.00		30,000		2.77	$	4.00		30,000	$	4.00	$	-
$	6.00		340,393		4.37	$	6.00		340,393	$	6.00	$	-
$	6.43		4,509,963		2.45	$	6.43		4,509,963	$	6.43	$	-
$	7.50		25,000		1.53	$	7.50		25,000	$	7.50	$	-
			5,245,749			$	6.39		5,245,749	$	6.39	$	47,655

Options

On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan.

On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. The Amendment was approved by the stockholders on January 23, 2025. As of January 31, 2026, with the February 1, 2025, automatic issuance of shares available under the Plan, 56,082 shares remain available for issuance of options under the Plan.

During the year ending January 31, 2026, 454,814 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $5.47- $6.85 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $1,383,732 and were recorded during the year ending January 31, 2026. The Company used the Black Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 96.55 %-108.35%; and a risk-free rate of 3.65%-3.91%.

The following table summarizes the changes in outstanding options and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 6 for the issuance of related party options.

				Exercise		Remaining		Intrinsic
	Shares			Price		Life		Value
Outstanding, January 31, 2025		1,373,668		$	3.23		1.90 years

Granted		454,834			6.35		1.90 years		-

Expired/Cancelled		(234,584	)		-		-

Exercised		(160,055	)		1.46		-

Outstanding, January 31, 2026		1,433,863			3.23		1.90 years

Granted		-			-		-

Expired/Cancelled		(30,000	)		3.98		-

Exercised		-			-		-

Outstanding - April 30, 2026		1,403,863		$	4.58		1.42 years	$	1,069,923

Exercisable - April 30, 2026		1,403,863		$	4.58		1.42 years	$	1,069,923

The following table summarizes additional information relating to the options outstanding as of April 30, 2026.

Range of Exercise Prices		Number Outstanding		Weighted Average Life (Years)		Weighted Average Exercise Price for Shares Outstanding		Number Exercisable		Weighted Average Exercise Price for Shares Exercisable		Intrinsic Value

$	1.93		206,945		0.49	$	1.93		206,945	$	1.93	$	401,473
$	2.12		70,000		0.49	$	2.12		70,000	$	2.12	$	122,500
$	2.37		182,500		0.88	$	2.37		182,500	$	2.37	$	273,750
$	2.61		170,000		0.88	$	2.61		170,000	$	2.61	$	214,200
$	2.65		20,000		0.39	$	2.65		20,000	$	2.65	$	24,400
$	2.75		30,000		0.76	$	2.75		30,000	$	2.75	$	33,600
$	5.47		45,667		2.75	$	5.47		45,667	$	5.47	$	-
$	5.99		30,000		1.17	$	5.99		30,000	$	5.99	$	-
$	6.22		260,833		2.31	$	6.22		260,833	$	6.22	$	-
$	6.84		108,334		2.31	$	6.84		108,334	$	6.84	$	-
$	6.85		40,000		2.29	$	6.85		40,000	$	6.85	$	-
$	7.34		180,918		1.73	$	7.34		180,918	$	7.34	$	-
$	8.07		58,666		1.73	$	8.07		58,666	$	8.07	$	-
			1,403,863		1.42	$	4.57	$	1,403,863	$	4.57	$	1,069,923

SEGMENT REPORTING

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer- decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

	Three Months Ending
	April 30,
	2026		2025
Net Sales
Pocono Pharmaceuticals	$	433,399	$	667,432
4P Therapeutics		-		-
Total		433,399		667,432
Gross Profit
Pocono Pharmaceuticals		196,801		251,981
4P Therapeutics		-		-
Total		196,801		251,981

Operating Expense
Selling, general and administrative - Pocono Pharmaceuticals		156,788		151,528
Selling, general and administrative - 4P Therapeutics		6,483		19,999
Selling, general and administrative - Corporate		1,049,734		810,525
Goodwill and intangibles impairment		-		-
Research and development - 4P Therapeutics		238,229		683,426
Total		1,451,234		1,665,478

Depreciation and Amortization
Pocono Pharmaceuticals	$	24,910	$	42,813
Corporate		-		-
4P Therapeutics		9,267		9,267
Total	$	34,177	$	57,480

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

	Three Months Ending
	April 30,
	2026		2025
Net Sales
United States	$	433,399	$	667,432
Outside the United States		-		-
Total	$	433,399	$	667,432

Property and equipment, not of accumulated depreciation	April 30, 2026		January 31, 2026
United States	$	548,244	$	567,255
Outside of the United States		-		-
Total	$	548,244	$	567,255

Assets
Corporate	$	3,818,051	$	4,437,703
Pocono Pharmaceuticals		1,825,258		1,820,731
4P Therapeutics		1,248,993		1,294,501
Total	$	6,892,302	$	7,547,935

10.

COMMITMENTS AND CONTINGENCIES

Employment Agreements

The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000. These agreements, and the employment of Mr. Goodman, automatically renew for one-year terms following expiration of the initial three-year terms and each successive one-year term.

The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

Kindeva Drug Delivery Agreement

On January 4, 2024, the Company signed a commercial development and clinical supply agreement for their lead product, Aversa Fentanyl, with Kindeva Drug Delivery, L.P. (“Kindeva”). Under this agreement, Kindeva will perform commercial manufacturing process development, manufacturing of clinical supplies for the human abuse liability clinical study, and development of chemistry, manufacturing and controls (CMC) information required by the FDA in support of a New Drug Application (“NDA”). As of April 30, 2026, the Company has incurred expenses of $5.2 million under this agreement. On February 4, 2025, the agreement was amended to reduce the hourly rate for the labor on the project in exchange for a milestone payment payable upon FDA approval. Under the amended Kindeva agreement, the remaining budget as of April 30, 2026, through NDA submission for the current workplan is $3.4 million. The amended agreement also includes a milestone payment of $3.0 million to be paid to Kindeva when the Company receives FDA approval.

Lease Agreement

On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expired on January 31, 2025. The lease has been extended for an additional three years at the same monthly rental.

Sorrento Therapeutics, Inc. Agreement

On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of April 30, 2026.

Legal Proceedings

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

Currently, there are no pending hearings or motions, and the case is in the discovery stage. In early 2024, the plaintiffs proposed a settlement offer of $100,000. The Company has not responded to that proposed settlement offer.

Termination Agreement

On February 13, 2026, the Company’s Board of Directors approved the termination immediately of the Company’s agreement for the sale of its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc., due to the purchaser’s failure to pay applicable late fees under the purchase agreement for their not closing on the December 31, 2025 closing date under the purchase agreement. The Company received $30,000 in late fees but have not received any further payments since January 21, 2026.

11.

SUBSEQUENT EVENTS

(a)

On June 1, 2026, the Company and TII Jet Services amended their credit line facility agreement in light of the expiration of the facility in the near future. The parties extended the $5 million credit line to June 30,2029. At this time, the Company has no outstanding drawn-down amounts under this facility.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the year ended January 31, 2026, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Overview

Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA^™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.

The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs contract research and development related services for pharmaceutical and medical devices customers. We manage and evaluate our operations, and report our financial results, through these two separate subsidiaries.

Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. We primarily operate and derive most of our revenues in the United States.

Recent Developments

On February 13, 2025, we signed an addendum to the Commercial Development and Clinical Supply Agreement for our lead product, Aversa™ Fentanyl, being developed with our partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products. Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. The development work being conducted under this agreement supports the development of Nutriband’s AVERSA™ abuse-deterrent technology in general, which can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants.

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

Our Business

AVERSA Abuse Deterrent Transdermal Products

Our lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. We believe that our AVERSA technology can be broadly applied to various transdermal products, and our plan is to follow the development of AVERSA Fentanyl with the development of additional abuse deterrent transdermal products for pharmaceuticals that have a risk or history of abuse, misuse or accidental exposure. Specifically, we have expanded our development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery.

In January 2024, we signed a commercial development and clinical supply agreement with Kindeva Drug Delivery, formerly 3M Drug Delivery (“Kindeva”), for the development of AVERSA Fentanyl using Kindeva’s FDA-approved fentanyl patch. This agreement replaced the previous feasibility agreement between the two companies which was focused on establishing the feasibility of incorporating our AVERSA abuse deterrent transdermal technology into Kindeva’s commercial transdermal manufacturing process. The commercial development and clinical supply agreement is focused on developing the commercial manufacturing process for AVERSA Fentanyl.

On November 1, 2021, The Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”), and the Plan then adopted provided for an initial 350,000 shares to issue and sell upon the exercise of stock options issued under the Plan.

The Plan provides for an automatic annual increase to be added on February 1 of each year equal to the lesser of (i) 250,000 shares of Common Equity or (ii) five percent (5%) of the total shares of Common Stock outstanding on such date (including for this purpose any shares of Common Stock issuable upon conversion of any outstanding capital equity of the Company) or (iii) such lesser number as determined by the Board. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. On March 20, 2024, our Board of Directors adopted an amendment to the Plan increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). We submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting, and the Amendment was approved by a majority vote of our stockholders. As of June 15, 2026, with the February 1, 2026 automatic increase of shares available for issuance under the Plan, 336,102 shares remain available for issuance of options under the Plan.

On August 5, 2025, the Company issued a preferred stock dividend of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) to its shareholders of record July 25, 2025. Each share of Series A Preferred Stock has the par value of $0.001 per share and is is convertible at the option of the holder into one share of Common Stock following the date of the approval for commercial sale by the Federal Drug Administration of the Company’s transdermal pharmaceutical products that are based on the Company’s AVERSA^™abuse deterrent t technology. The holders of Series A Preferred Stock that do not convert their shares shall be eligible for dividends as declared by the Board of Directors for those holders, and the Series A Preferred is also eligible for dividends declared by the Board of Directors on the class of common stock. In the preferred stock dividend, 3,008,643 shares of the Series A Preferred Stock (including shares of common stock issued to stockholders exercising warrants following the distribution of the dividend) were issued to our stockholders. The fair value of the dividend was $21,814,166.

Results of Operations

Three Months Ended April 30, 2026 and 2025

For the three months ending April 30, 2026, we generated revenue of $433,399 and our revenue costs were $236,598, resulting in a gross profit of $196,801. For the three months ending April 30, 2025, we generated revenue of $667,432 and our costs of revenue were $415,451, resulting in a gross profit of $251,981. Our revenue for the three months ending April 30, 2026, was derived from sales from our Pocono Pharmaceuticals segment and $-0- from contract research and development services from our 4P Therapeutics segment. The revenue from the Pocono Pharmaceuticals segment decreased from the prior year as one of the Company’s principal customers moved their operations to Asia. A decrease in demand is expected in the balance of the current year. There were no sales in our 4P Therapeutics segment in the current year due to a shift in focus and the main contract wound down in the prior year. The increase in gross margin is due primarily to higher margins in our sales mix.

For the three months ending April 30, 2026, our selling, general and administrative expenses were $1,203,891, primarily legal, accounting and compensation expenses compared to $982,052 for the three months ending April 30, 2025. The increase from 2025 is primarily attributable to increases in compensation-based expenses.

During the three months ending April 30, 2026, the Company incurred research and development expenses of its Aversa Fentanyl product of $247,261, primarily of salaries and development costs from Kindeva as compared to $683,426 for the three months ending April 30, 2025. The decrease is primarily attributable to a reduction in labor costs.

We incurred interest expenses of $5,008 for the three months ending April 30, 2026, as compared to $5,880 for the three months ending April 30, 2025.

Interest income for the three months ending April 30, 2026 was $17,403 as compared to $30,508 for the three months ending April 30, 2025. The decrease is primarily due to a decrease in cash used in the Company’s operations.

As a result of the foregoing, we sustained a net loss of $1,241,956 for the three months ending April 30, 2026, or ($0.10) per share (basic and diluted), compared with a loss of $1,388,869, or $(0.12) per share (basic and diluted) for the three months ending April 30, 2025.

Liquidity and Capital Resources

As of April 30, 2026 we had $4,006,184 in cash and cash equivalents and working capital of $3,544,125, as compared with cash and cash equivalents of $4,574,857 and working capital of $4,204,437 as of January 31, 2026.

For the three months ending April 30, 2026, we used cash of $563,104 in our operations. The principal adjustments to our net loss of $1,241,956 were depreciation and amortization of $34,177, and the issuance of warrants for services in the amount of $552,458.

For the three months ending April 30, 2026, no cash was provided from financing activities .

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

Critical accounting policies remained relatively consistent from the year ended January 31, 2026.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures.

As of the end of period covered by this report, we carried out an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, we concluded that our disclosure controls and procedures are not effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, and excessive reliance on third-party consultants for accounting, financial reporting and related activities. During the past fiscal year, we have added qualified accounting personnel, so the Company does not have to rely on third-party consultants. The Company has established additional monitoring controls over the financial statements. We have also improved our internal controls to provide for a detailed accounting review of all revenue items and accounts receivable and accounts payable transactions in connection with the entry and categorization of each transaction in the preparation of the Company’s financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Changes in internal controls over financial reporting.

No changes were made to our internal controls in the quarterly period covered by this report that have materially affected, or are reasonably likely materially to affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

With respect to legal proceedings that arise in the ordinary course of business, when the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated.

ITEM 1A. RISK FACTORS

You should carefully consider the key risks described below together with all of the other information included in this report and our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 29, 2026, before making an investment decision with regard to our securities. The risks set forth below and in our Form 10-K are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant part of your investment.

The United States at the time of this filing is involved with a war with Iran, the outcome of which could result in changes adverse to us in domestic and international markets, including on tariffs and health care and medical products. These changes could affect our promotional activities and our profitability and margins. Additionally, many of the effects and consequences of U.S. and global financial and economic conditions and current stock market trends, which are concentrating on companies in the artificial intelligence development market, could potentially have a material adverse effect on our liquidity and capital resources, including the ability to raise additional capital, if needed, or could otherwise negatively affect our business and financial results.

There is further economic uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA.

Our operating results could be affected by the current political and economic uncertainties related to the economy of the United States, the domestic pharmaceutical industry and world economies. Future conditions may also adversely affect our pricing strategy, promotional activities and our profitability and margins. Additionally, many of the effects and consequences of U.S. and global financial and economic conditions could potentially have a material adverse effect on our liquidity and capital resources, including the ability to raise additional capital, if needed, or could otherwise negatively affect our business and financial results. Market instability could make it more difficult for us and our suppliers to accurately forecast future product demand trends. Additionally, inflationary factors such as increases in the costs to purchase products, acquire product rights and overhead costs may adversely affect our operating results.

In this economic environment, we are also subject to the risks common to low-revenue start-up enterprises, including, among other factors, undercapitalization, cash shortages, limitations with respect to personnel, financial and other capital or operating expenditures. Drug development companies typically incur substantial losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug has received FDA approval, which cannot be assured, and until the company has started to sell the product. We can give no assurance that we can or will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early stage of operations. We cannot assure you that we will be able to operate profitably or generate positive cash flow. If we cannot achieve profitability, we may be forced to cease operations and you may suffer a total loss of your investment.

Because we do not have a product we can market in the United States, we cannot predict when or whether we will operate profitably.

We have not completed the development of our lead product, which is our abuse deterrent fentanyl transdermal system, and we do not have any product that we can market in the United States. Because of the numerous risks and uncertainties associated with product development, we cannot assure you that we will be able to develop and market any products or achieve or attain profitability. If we are able to obtain financing for our operations, we expect that we will incur substantial expenses as we continue with our product development and clinical trials. Further, if we are required by applicable regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which we may seek to market product, to perform studies in addition to those we currently anticipate, our expenses will increase beyond expectations and the timing of any potential product approval may be delayed. As a result, we could continue to incur substantial losses and negative cash flow as long as these negative factors continue in effect.

A number of factors, including, but not limited to the following, may affect our ability to develop our business and operate profitably:

●

our ability to obtain necessary funding to develop our proposed products;

●

the success of clinical trials for our products;

●

our ability to obtain FDA approval for us to market any proposed product in our pipeline in the United States;

●

any delays in regulatory review and approval of product in development;

●

if we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing and distribution agreements with qualified third parties;

●

market acceptance of our products;

●

our ability to establish an effective sales and marketing infrastructure;

●

our ability to protect our intellectual property;

●

competition from existing products or new products that may emerge;

●

potential product liability claims and adverse events;

●

our ability to adequately support future growth; and

●

our ability to attract and retain key personnel to manage our business effectively.

Our stock price has been and is likely to continue to be volatile and you may not be able to resell shares of our common stock at or above the price you paid, if at all.

The trading price of our common stock has experienced fluctuations due to the factors discussed in these risk factors. In addition, the stock market in general has, and the NASDAQ Capital Market and technology companies in particular have, experienced extreme price and volume fluctuations. These trading prices and valuations may not be sustainable. These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against companies (primarily those that are larger than us) that experienced such volatility. This type of litigation, if instituted against us, regardless of its outcome, could result in substantial costs and a diversion of our management’s attention and resources.

Stockholders may experience significant dilution as a result of future equity offerings and other issuances of our common stock or other securities.

We will need to raise substantial funds in order to develop our products. In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may be based on a discount from market at the time of issuance. Stockholders will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition, the sale of shares and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.

The drug delivery industry is subject to rapid technological change, and our failure to keep up with technological developments may impair our ability to market our products.

Our products use technology which we developed for the transdermal delivery of drugs. The field of drug delivery is subject to rapid technological changes. Our future success will depend upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing customer requirements. If we cannot keep pace with such changes and advances, our proposed products could be rendered obsolete, which would result in our having to cease its operations.

ITEM 5. OTHER INFORMATION

ITEM 6. EXHIBITS.

Exhibit Number		Description of Exhibits
31.1		Section 302 Certification of Chief Executive Officer.
31.2		Section 302 Certification of Chief Financial Officer.
32.1		Section 906 Certification of Chief Executive Officer.
32.2		Section 906 Certification of Chief Financial Officer.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUTRIBAND INC.

June 11, 2026	By:	/s/ Gareth Sheridan
		Gareth Sheridan, Chief Executive Officer
		(Principal Executive Officer)

June 11, 2026
	By:	/s/ Gerald Goodman
		Gerald Goodman, Chief Financial Officer
		(Principal Financial Officer)

NutriBand Inc. 10-Q